NASDAQ: MTVAMetavia Inc Stock
$2.45-0.12 (-4.67%)
Updated Dec 4, 2024
MTVA Price
$2.45
Fair Value Price
N/A
Market Cap
$21.11M
52 Week Low
$2.08
52 Week High
$6.75
P/E
-0.52x
P/B
1.63x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$27.73M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.71
Operating Cash Flow
-$23M
Beta
0.78
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MTVA Overview
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MTVA's potential to beat the market
- MTVA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MTVA
RankedUnranked of 335
RankedUnranked of 335
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $26.49 | A | |
| $7.53 | A | |
| $123.45 | A |
Be the first to know about important MTVA news, forecast changes, insider trades & much more!
MTVA News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MTVA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MTVA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MTVA is good value based on its book value relative to its share price (1.63x), compared to the US Biotechnology industry average (5.6x)
P/B vs Industry Valuation
MTVA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MTVA due diligence checks available for Premium users.
Valuation
MTVA fair value
Fair Value of MTVA stock based on Discounted Cash Flow (DCF)
Price
$2.45
Fair Value
$4.38
Undervalued by
44.12%
MTVA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MTVA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.52x
Industry
-98.09x
Market
28.79x
MTVA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.63x
Industry
5.6x
MTVA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MTVA's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.7M
Profit Margin
0%
MTVA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$22.1M
Liabilities
$9.2M
Debt to equity
0.71
MTVA's short-term assets ($21.94M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MTVA's short-term assets ($21.94M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MTVA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MTVA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.6M
Investing
$0.0
Financing
-$676.0k
MTVA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MTVA vs Biotech Stocks
Metavia Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.